MedTrace Logo

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®

NCT00542880 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 442

Last updated 2012-08-30

Study results available
· View outcomes & findings →

Summary

This study is to assess the effects with two different inhaled respiratory medications with regards to improvement of lung function, symptoms and morning activities.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg

DRUG

Seretide Diskus (salmeterol/fluticasone) 50/500 μg

Sponsors & Collaborators

Principal Investigators

  • Tomas Andersson, MD · AstraZeneca

  • Martyn R Partridge, MD FRCP · Faculty of Medicine, Imperial College, NHLI at Charing Cross Hospital, LONDON, UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Denmark
  • Germany
  • India
  • Philippines
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00542880 on ClinicalTrials.gov